Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers

Abstract Background Breast cancers with 1–10% cell staining for estrogen receptor (ER) present particular clinical features. The clinical data of estrogen receptor expression level and treatment effect are limited, particularly regarding chemotherapy benefit. We evaluated the pathologic response to...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Hai-long Chen, Feng-bo Huang, Qiang Chen, Yong-chuan Deng
Μορφή:	Άρθρο
Γλώσσα:	English
Έκδοση:	BMC 2023-09-01
Σειρά:	BMC Cancer
Θέματα:	Breast cancer Estrogen receptor Neoadjuvant chemotherapy Pathologic complete response Prognosis
Διαθέσιμο Online:	https://doi.org/10.1186/s12885-023-11368-2

Παρόμοια τεκμήρια

Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy
ανά: He Dou, κ.ά.
Έκδοση: (2024-01-01)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
ανά: I.P.C. Buzatto, κ.ά.

Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
ανά: Yingbo Shao, κ.ά.
Έκδοση: (2025-03-01)

Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy
ανά: Yingbo Shao, κ.ά.
Έκδοση: (2024-02-01)

Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
ανά: In Hee Lee, κ.ά.
Έκδοση: (2020-11-01)

Association of tumor‐infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer
ανά: Jin Hong, κ.ά.
Έκδοση: (2021-11-01)

Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study
ανά: Lingfeng Tang, κ.ά.
Έκδοση: (2024-05-01)

A real-world clinicopathological model for predicting pathological complete response to neoadjuvant chemotherapy in breast cancer
ανά: Shan Fang, κ.ά.
Έκδοση: (2024-02-01)

Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
ανά: Zhendong Shi, κ.ά.
Έκδοση: (2024-07-01)

Pathological complete response following neoadjuvant chemotherapy for locally advanced intrahepatic cholangiocarcinoma
ανά: Yoshitaka Shimamaki, κ.ά.
Έκδοση: (2024-02-01)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
ανά: Elina Sivina, κ.ά.
Έκδοση: (2023-03-01)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
ανά: Shuling Zhou, κ.ά.
Έκδοση: (2023-02-01)

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
ανά: Mengping Long, κ.ά.
Έκδοση: (2022-12-01)

Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancers
ανά: Ling-Ming Tseng, κ.ά.
Έκδοση: (2023-12-01)

Metabolic syndrome is a risk factor for breast cancer patients receiving neoadjuvant chemotherapy: A case-control study
ανά: Zhaoyue Zhou, κ.ά.
Έκδοση: (2023-01-01)

Survival outcomes of locally advanced gastric cancer cases with pathological complete response received neoadjuvant chemotherapy
ανά: Qing Hu, κ.ά.
Έκδοση: (2021-06-01)

The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery
ανά: Mina M. G. Youssef, κ.ά.
Έκδοση: (2021-02-01)

Short- and long-term outcomes of neoadjuvant chemotherapy compared with neoadjuvant chemoradiotherapy for locally advanced rectal cancer: an updated meta-analysis
ανά: Yue Guo, κ.ά.
Έκδοση: (2025-02-01)

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
ανά: Sungchan Gwark, κ.ά.
Έκδοση: (2021-09-01)

Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy
ανά: Cui Jiang, κ.ά.
Έκδοση: (2019-09-01)

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning
ανά: Witali Aswolinskiy, κ.ά.
Έκδοση: (2023-11-01)

Factors predicting pathological complete response to neoadjuvant chemotherapy in patients diagnosed with non-metastatic muscle invasive urothelial bladder cancer
ανά: Zuhat Urakçı, κ.ά.
Έκδοση: (2023-10-01)

Markers Associated With Tumor Recurrence in Patients With Breast Cancer Achieving a Pathologic Complete Response After Neoadjuvant Chemotherapy
ανά: Li-Yun Xie, κ.ά.
Έκδοση: (2022-04-01)

Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study
ανά: Lingfeng Tang, κ.ά.
Έκδοση: (2022-12-01)

SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival
ανά: Ruo-Xi Wang, κ.ά.
Έκδοση: (2022-10-01)

Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis
ανά: Samuel Rosner, MD, κ.ά.
Έκδοση: (2022-09-01)

Imaging‐proteomic analysis for prediction of neoadjuvant chemotherapy responses in patients with breast cancer
ανά: Jingxian Duan, κ.ά.
Έκδοση: (2023-12-01)

Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
ανά: Jung Hwan Ji, κ.ά.
Έκδοση: (2023-01-01)

Neoadjuvant chemotherapy efficacy and prognosis in HER2-low and HER2-zero breast cancer patients by HR status: a retrospective study in China
ανά: Shaorong Zhao, κ.ά.
Έκδοση: (2024-05-01)

Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB
ανά: Pingping Liu, κ.ά.
Έκδοση: (2022-04-01)

Accuracy of core biopsy image-guided post-neoadjuvant chemotherapy breast to predict pathologic complete response
ανά: P. V. Krivorotko, κ.ά.
Έκδοση: (2022-12-01)

Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study
ανά: WANG Ruoxi, JI Peng, GONG Yue, CHEN Sheng
Έκδοση: (2023-07-01)

An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer
ανά: Changfang Fu, κ.ά.
Έκδοση: (2021-08-01)

A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy
ανά: Yanhua Chen, κ.ά.
Έκδοση: (2020-03-01)

A nomogram for predicting pathologic node negativity after neoadjuvant chemotherapy in breast cancer patients: a nationwide, multicenter retrospective cohort study (CSBrS-012)
ανά: Amina Maimaitiaili, κ.ά.
Έκδοση: (2024-05-01)

Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy
ανά: Yushi Liu, κ.ά.
Έκδοση: (2022-06-01)

Construction of a nomogram prediction model for the pathological complete response after neoadjuvant chemotherapy in breast cancer: a study based on ultrasound and clinicopathological features
ανά: Pingjuan Ni, κ.ά.
Έκδοση: (2025-03-01)

Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
ανά: Lucas MW, κ.ά.
Έκδοση: (2022-08-01)

Predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients based on ultrasound longitudinal temporal depth network fusion model
ανά: Xiaodan Feng, κ.ά.
Έκδοση: (2025-02-01)

Are baseline ultrasound and mammographic features associated with rates of pathological completes response in patients receiving neoadjuvant chemotherapy for breast cancer?
ανά: Sarah L. Savaridas, κ.ά.
Έκδοση: (2019-10-01)